These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32470436)

  • 1. Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
    Krishnan A; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e445-e446. PubMed ID: 32470436
    [No Abstract]   [Full Text] [Related]  

  • 2. [Induction therapy of transplant-eligible patients in multiple myeloma].
    Konishi J; Sunami K
    Nihon Rinsho; 2015 Jan; 73(1):90-4. PubMed ID: 25626311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical treatment of newly diagnosed multiple myeloma.
    Cejalvo MJ; de la Rubia J
    Expert Rev Hematol; 2015 Oct; 8(5):595-611. PubMed ID: 26327587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of consolidation therapy in transplant eligible multiple myeloma patients.
    Cavo M; Brioli A; Tacchetti P; Zannetti BA; Mancuso K; Zamagni E
    Semin Oncol; 2013 Oct; 40(5):610-7. PubMed ID: 24135406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
    Mina R; Petrucci MT; Corradini P; Spada S; Patriarca F; Cerrato C; De Paoli L; Pescosta N; Ria R; Malfitano A; Musto P; Baldini L; Guglielmelli T; Gamberi B; Mannina D; Benevolo G; Zambello R; Falcone AP; Palumbo A; Nagler A; Calafiore V; Hájek R; Spencer A; Boccadoro M; Bringhen S
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):533-540. PubMed ID: 29910180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
    Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
    J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of transplant-eligible symptomatic multiple myeloma].
    Nakaseko C
    Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of transplant-eligible patients with multiple myeloma in 2014.
    Landau H; Giralt S
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):815-27. PubMed ID: 25212884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
    Joks M; Jurczyszyn A; Machaczka M; Skotnicki AB; Komarnicki M
    Eur J Haematol; 2015 Feb; 94(2):109-14. PubMed ID: 25039659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy.
    Huang W; Li J; Li H; Kang W; Bo J; Zhao Y; Gao C; Zhou D; Yu L
    Leuk Lymphoma; 2012 Dec; 53(12):2507-10. PubMed ID: 22512306
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand.
    Chien N; Romeril K; Baker B; Goodman H; Chan H
    N Z Med J; 2020 Dec; 133(1527):104-110. PubMed ID: 33332332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing therapy for transplant-eligible patients with newly diagnosed multiple myeloma.
    Moreau P; Giralt SA
    Leuk Res; 2012 Nov; 36 Suppl 1():S13-8. PubMed ID: 23176719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers.
    Mohty M; Harousseau JL
    Haematologica; 2014 Mar; 99(3):408-16. PubMed ID: 24598852
    [No Abstract]   [Full Text] [Related]  

  • 17. Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
    Mangiacavalli S; Pochintesta L; Ravelli E; Baldini L; Ferretti VV; La Targia ML; Farina L; Cocito F; Cairoli R; Montefusco V; Corso A
    Leuk Lymphoma; 2015 Jun; 56(6):1901-2. PubMed ID: 25347423
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).
    Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K
    Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
    de Tute RM; Rawstron AC; Gregory WM; Child JA; Davies FE; Bell SE; Cook G; Szubert AJ; Drayson MT; Jackson GH; Morgan GJ; Owen RG
    Haematologica; 2016 Feb; 101(2):e69-71. PubMed ID: 26471484
    [No Abstract]   [Full Text] [Related]  

  • 20. Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?
    Jiménez-Ubieto A; Paiva B; Puig N; Cedena MT; Martínez-López J; Oriol A; Blanchard MJ; Ríos R; Martin J; Martínez R; Sureda A; Hernández MT; de la Rubia J; Krnisk I; Cabañas V; Palomera L; Sánchez-Pina JM; Bargay J; Mateos MV; Rosiñol L; Blade J; San Miguel J; Lahuerta JJ;
    Blood; 2021 Nov; 138(19):1901-1905. PubMed ID: 34329372
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.